Stereotactic body radiotherapy for hepatocellular carcinoma: Five-year prospective registry outcomes from an Australian tertiary transplant centre

doi:10.3748/wjg.118570

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 32, Issue 32

This Article

(15)

(16)

(0)

(139)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Prospective Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastroenterol. Aug 28, 2026; 32(32): 118570
Published online Aug 28, 2026. doi: 10.3748/wjg.118570

Table 1 Patient characteristics at baseline, n (%)

Variable	n = 58
Median age (IQR)	66.5 (60-74)
Gender
Male	47 (81.03)
Female	11 (18.97)
ECOG
0	52 (89.66)
1	3 (5.17)
2⁺	3 (5.17)
Liver cirrhosis
No	4 (6.90)
Yes	54 (93.10)
Pre-existing liver disease
HBV	9 (15.52)
HCV	24 (41.38)
EtOH	19 (32.76)
MASLD	14 (24.14)
Other	2 (3.45)
Unsure/unknown	2 (3.45)
Nil	2 (3.45)
Child-Pugh status
5	20 (34.48)
6	23 (39.66)
7	5 (8.62)
8	6 (10.34)
ALBI
Grade 1	13 (22.41)
Grade 2	43 (74.14)
Grade 3	2 (3.45)
MELD
< 10	28 (48.28)
10-19	26 (44.83)
> 20	4 (6.90)

ECOG: Eastern Cooperative Oncology Group; HBV: Hepatitis B virus; HCV: Hepatitis C virus; EtOH: Alcohol-related liver disease; MASLD: Metabolic dysfunction-associated steatotic liver disease; ALBI: Albumin-bilirubin; MELD: Model for end-stage liver disease; IQR: Interquartile range.

Full Size Table

Citation: Fong SC, Ng SP, Italiano D, Chung W, Vaz K, Fink M, Goodwin M, Ranatunga D, Khor R. Stereotactic body radiotherapy for hepatocellular carcinoma: Five-year prospective registry outcomes from an Australian tertiary transplant centre. World J Gastroenterol 2026; 32(32): 118570
URL: https://www.wjgnet.com/1007-9327/full/v32/i32/118570.htm
DOI: https://dx.doi.org/10.3748/wjg.118570

Fong SC, Ng SP, Italiano D, Chung W, Vaz K, Fink M, Goodwin M, Ranatunga D, Khor R. Stereotactic body radiotherapy for hepatocellular carcinoma: Five-year prospective registry outcomes from an Australian tertiary transplant centre. World J Gastroenterol 2026; 32(32): 118570 [DOI: 10.3748/wjg.118570]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.